MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Voss, M. H.; Garmezy, B.; Kim, S. H.; Rey, J. P. M.; Mansinho, A. B.; Rodriguez-Vida, A.; Oliveira, J.; van Dongen, M.; Medina RodrÃguez, L.; Negrier, S.; Tran, B.; Carneiro, B. A.; Castanon Alvarez, E.; Rha, S. Y.; Wang, Y.; Gainer, S. D.; Tang, Z.; Achour, I.; Asare, J. M.; Albiges, L. |
| Abstract Title: | MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1012 |
| Language: | English |
| ACCESSION: | WOS:001087480202548 |
| DOI: | 10.1016/j.annonc.2023.09.1113 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1883MO -- Source: Wos |
